Drug intelligence / Profile preview

rituximab + bendamustine + mitoxantrone + dexamethasone

Development stage: Unknown
Lead developer: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

RBMD is a combination chemotherapy regimen used primarily for treating relapsed or refractory follicular lymphoma. It consists of rituximab (an anti-CD20 monoclonal antibody), bendamustine (an alkylating agent), mitoxantrone (an anthracenedione antineoplastic agent), and dexamethasone (a corticosteroid). This response-adapted treatment protocol has shown high efficacy in patients who relapsed after or were refractory to first-line immunochemotherapy, with an overall response rate of 88.3% and complete remission rate of 70%.

Other names: R-BMD regimen

Targets

TOP2A (DNA topoisomerase II)CD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on rituximab + bendamustine + mitoxantrone + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rituximab + bendamustine + mitoxantrone + dexamethasone.

Explore the full profile